These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32678492)

  • 1. FOXO1 inactivation induces cisplatin resistance in bladder cancer.
    Ide H; Goto T; Teramoto Y; Mizushima T; Jiang G; Nagata Y; Inoue S; Baras AS; Kashiwagi E; Miyamoto H
    Cancer Sci; 2020 Sep; 111(9):3397-3400. PubMed ID: 32678492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
    Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
    Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
    Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
    Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.
    Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL
    Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
    Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
    Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Goodspeed A; Jean A; Costello JC
    Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim.
    Sun T; Zhang J; Deng B; Fan X; Long T; Jin H; Tao S; Kang P; Tan Q
    Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1348-1359. PubMed ID: 33167006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.
    Kashiwagi E; Inoue S; Mizushima T; Chen J; Ide H; Kawahara T; Reis LO; Baras AS; Netto GJ; Miyamoto H
    Br J Cancer; 2018 Jan; 118(2):213-223. PubMed ID: 29123257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
    Chen C; Han G; Li Y; Yue Z; Wang L; Liu J
    J Cell Biochem; 2019 Jan; 120(1):882-893. PubMed ID: 30216501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
    Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
    Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-1/GOLPH3/Foxo1 Signaling Pathway Regulates Proliferation of Bladder Cancer.
    Liu MK; Ma T; Yu Y; Suo Y; Li K; Song SC; Zhang W
    Technol Cancer Res Treat; 2019; 18():1533033819886897. PubMed ID: 31714185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
    Li Y; Zu X; Hu X; Wang L; He W
    Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
    Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
    Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
    Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
    Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
    Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
    Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
    [No Abstract]   [Full Text] [Related]  

  • 17. FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells.
    Ide H; Mizushima T; Jiang G; Goto T; Nagata Y; Teramoto Y; Inoue S; Li Y; Kashiwagi E; Baras AS; Netto GJ; Kawahara T; Miyamoto H
    Endocr Relat Cancer; 2020 Apr; 27(4):231-244. PubMed ID: 32031965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
    Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
    Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
    Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin.
    Shiota M; Tsunoda T; Song Y; Yokomizo A; Tada Y; Oda Y; Naito S
    BJU Int; 2011 Apr; 107(7):1148-53. PubMed ID: 20726978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.